High incidence of cardiovascular events in patients with rheumatoid arthritis

Rheumatoid arthritis (RA) is associated with higher risk for cardiovascular disease (CVD) in comparison with the general population. Traditional cardiovascular (CV) risk factors only partially explain the higher risk for CVD. There is increasing evidence that inflammation explains the enhanced CV risk in RA, as inflammation has a pivotal role in the development of atherosclerotic disease and this might be the link between increased atherosclerotic CVD and RA. Other RA-related factors might be undertreatment of CV comorbidity, and the use of non-steroidal anti-inflammatory drugs (NSAIDs) or selective cyclo-oxygenase 2 inhibitors.

The objective of this prospective observational study was to determine the incidence of CV events in patients with RA in comparison to the general Dutch population, where the incidence of CV events is 1% per year.

Between September 2003 and August 2004 12,532 questionnaires were sent to 4,125 patients with RA. In all, 2,099 patients (51%) returned at least 1 questionnaire and 1,086 patients (25%) returned 1557 patient years. The annual incidence of CV events was 2.6 (95% CI 1.8 to 3.4) per 100 patient years. CV events occurred in 41 patients: 19 patients experienced coronary events, 14 patients experienced cerebrovascular events and 8 patients experienced peripheral arterial events (table 1). We observed a more than twofold increase in the incidence of CV events in RA in comparison to the general Dutch population. The age-adjusted incidence of ischaemic heart and cerebrovascular diseases in the general Dutch population was 1.0%, versus 2.6% in our RA population. As the RA population encompassed relatively more women than the general population our findings probably underestimate the true CV risk in RA. As expected, established CV risk factors as higher age, male gender, smoking and (family) history for CVD as well as statin use, were associated with a higher risk for CVD.

Patients with CV events used a lower dose of methotrexate than patients without CV events, which is in line with other studies, demonstrating the CV protective effect of methotrexate, probably mediated by inflammation suppression.

The observed association between acetaminophen use and antihypertensive use, might be due to the induction of hypertension mediated by cyclo-oxygenase 2 inhibition. This observation confirms earlier literature findings and necessitates prospective investigations.

Cyclo-oxygenase 2 inhibitors and most NSAIDs are associated with an increased CV risk. In the present study patients with CV events used less NSAIDs prior to the event in comparison to the patients without CV events. This is probably the result of restrained prescriptions of cyclo-oxygenase 2 inhibitors and NSAIDs to patients who were high risk for CVD and demonstrates the potentially strong effects of unmeasured confounding in observational studies.

Two limitations of this study should be discussed. Firstly, the relatively low response rate of 51% could result in a selection bias. Therefore, we compared the baseline characteristics between the responders and non-responders and found no differences rendering this bias unlikely. Secondly, the small number of events in our case-control substudy makes it difficult to reach final conclusions about CV risk factors. Future studies are needed to further elucidate these topics.

Altogether, this study reveals a doubled incidence of CV events in RA in comparison to the general Dutch population, strengthening the case for CV risk management in RA.

REFERENCES


K S S Steen, W F Lems, M Visman, M Heierman, B A C Dijkmans, J W R Twisk, M Boers, M T Nurmohamed

1 Department of Rheumatology, VU Medical Center, Amsterdam, The Netherlands; 2 Department of Rheumatology, Jan van Breemen Institute, Amsterdam, The Netherlands; 3 Department of Clinical Epidemiology and Biostatistics, VU Medical Center, Amsterdam, The Netherlands; 4 Institute of Health Sciences, VU Medical Center, Amsterdam, The Netherlands; 5 Department of Internal Medicine, VU Medical Center, Amsterdam, The Netherlands

Correspondence to: M T Nurmohamed, Department of Rheumatology, VU Medical Center, Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands; mt.nurmohamed@vumc.nl

Funding: This study was facilitated by the Jan van Breemen Institute Clinical Research Bureau that receives financial support of the Dutch Arthritis Foundation, and was financially supported by an unrestricted grant from AstraZeneca.

Competing interests: None declared.

Ethics approval: The VU University Medical Center and Jan van Breemen Institute gave ethical approval for this study.

Accepted 5 December 2008

Table 1  Characteristics of patients with rheumatoid arthritis (RA) with and without cardiovascular (CV) events

<table>
<thead>
<tr>
<th>Patients with CV events</th>
<th>Patients without CV events</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients with RA</td>
<td>41</td>
<td>2058</td>
</tr>
<tr>
<td>Mean age, years (range)</td>
<td>72 (56–84)</td>
<td>61 (19–94)</td>
</tr>
<tr>
<td>No. aged 60 years or older</td>
<td>36 (88)</td>
<td>1083 (53)</td>
</tr>
<tr>
<td>No. of females (%)</td>
<td>23 (56)</td>
<td>1157 (73)</td>
</tr>
<tr>
<td>Duration of RA in years (%):</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2</td>
<td>4 (1)</td>
<td>76 (5)</td>
</tr>
<tr>
<td>2–10</td>
<td>12 (43)</td>
<td>676 (49)</td>
</tr>
<tr>
<td>&gt;10</td>
<td>15 (54)</td>
<td>631 (46)</td>
</tr>
<tr>
<td>Unknown</td>
<td>13 (32)</td>
<td>675 (33)</td>
</tr>
<tr>
<td>No. of patients with history of GI event(s) (%)</td>
<td>7 (22)</td>
<td>175 (11)</td>
</tr>
<tr>
<td>No. of patients without history of GI event(s)</td>
<td>25 (78)</td>
<td>1362 (89)</td>
</tr>
<tr>
<td>Unknown</td>
<td>9 (22)</td>
<td>521 (25)</td>
</tr>
<tr>
<td>No. of high risk patients* (%)</td>
<td>38 (93)</td>
<td>1148 (56)</td>
</tr>
</tbody>
</table>

NSAIDs and cyclo-oxygenase 2 inhibitors (%): No NSAIDs 25 (61) 747 (38) <0.001
NSAIDs with low-dose aspirin 3 (7) 98 (5) 0.45
NSAIDs without low-dose aspirin 6 (15) 966 (47) <0.001
Cyclo-oxygenase 2 inhibitors with low-dose aspirin 0 30 (1) 1.00
Cyclo-oxygenase 2 inhibitors without low-dose aspirin 7 (17) 257 (12) 0.38
Acetaminophen (%) 14 (34) 624 (30) 0.60
Low-dose aspirin alone (%) 13 (32) 102 (5) <0.001
Low-dose aspirin, clopidogrel, dipyridamole† 18 (44) 236 (11) <0.001
Antiagulants§ (%) 13 (32) 103 (5) <0.001
Family history of CV events, no. (%) 22 (71) 924 (55) 0.07
Treatment for RA (%):
No DMARDs 8 (20) 307 (15) 0.38
Methotrexate 14 (34) 1224 (59) <0.001
Corticosteroids 16 (39) 432 (21) 0.01
Other DMARDs 9 (22) 373 (18) 0.53
Combination of DMARDs$ 10 (24) 501 (24) 1.00
Biologics¶ 5 (12) 322 (16) 0.06
Gastroprotection** (%) 19 (46) 895 (43) 0.73
Current or previous smoker (%) 32 (78) 1308 (64) 0.06
Antihypertensive drugs (%) 25 (61) 666 (32) <0.001
Oral diabetic drugs or insulin (%) 4 (10) 130 (6) 0.33
Statins (%) 18 (44) 251 (12) <0.001

*High risk: higher age and/or previous GI event.
†Low-dose aspirin, clopidogrel and dipyridamole are used in secondary prevention for CV event.
§Combination of DMARDs: two or more DMARDs, corticosteroids included.
¶Biologics: adalimumab, infliximab, etanercept and anakinra.
**Gastroprotection: proton pump inhibitors (PPIs), prostaglandin analogue and high dose of H2 antagonists (other: PA or H2A) and cyclo-oxygenase 2 inhibitors.
DMARDs, disease-modifying antirheumatic drugs; GI, gastrointestinal; NSAIDs, non-steroidal anti-inflammatory drugs.

REFERENCES

High incidence of cardiovascular events in patients with rheumatoid arthritis


Ann Rheum Dis 2009 68: 1509-1510
doi: 10.1136/ard.2008.105023

Updated information and services can be found at:
http://ard.bmj.com/content/68/9/1509.full.html

These include:

References
This article cites 9 articles, 1 of which can be accessed free at:
http://ard.bmj.com/content/68/9/1509.full.html#ref-list-1

Article cited in:
http://ard.bmj.com/content/68/9/1509.full.html#related-urls

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/